Recovery & repair
LL-37
Cathelicidin antimicrobial peptide · CAMP · 37-aa · antimicrobial
A naturally occurring antimicrobial peptide studied for wound healing and immune defence — one of the least human-tested peptides in this library.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
LL-37 is part of the human innate immune system, produced by skin and immune cells to help fight bacteria and support wound healing. Its natural role is well established in lab research.
As a marketed 'immune defence' peptide, the evidence gap is unusually wide: almost everything known comes from in-vitro and animal wound models. There is essentially no published human trial of injectable or topical LL-37 for the general-health claims it's sold under.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Antimicrobial and immune defence support”
Well documented in cell and animal studies as part of the natural immune system; not proven as a supplement.
Claim-level citation mapping is in progress.
“Speeds wound healing”
Plausible from lab wound-healing models; no human clinical trials for this use.
Claim-level citation mapping is in progress.
“General immune-system 'boost'”
A vague marketing claim with no direct human evidence behind it.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Not a licensed medicine or approved supplement in the UK — a research chemical with no legal human-use route.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
A niche, lower-volume topic even within peptide communities — most discussion is speculative or mechanism-focused rather than first-hand reports.
Where they’re talking
- r/PeptidesLow volume, mostly mechanism/science-focused threads.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
- 4.Buying medicines online · European Medicines Agency